⌘K
Loading ticker…
As of 2026-08-24, Clorox Company (CLX) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 49. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.8%, relative volume 0.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
CLX is held by 57 ETFs as of May 2026. Top owner: NOBL at 1.32% weight, $147M notional. Top 3 carry $245M.
Held by 216 ETFs · $3.2B across latest filings · largest weight 4.40% (MVAL).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| NOBLProShares S&P 500 Dividend Aristocrats ETF | 1.32% | $147M | −0.27 pp |
| SPHD | 1.69% | $55M | −0.54 pp |
| VDCVanguard Consumer Staples ETF | 0.47% | $43M | −0.13 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.20% | $29M | −0.11 pp |
| ESGU |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.10% |
| $17M |
| −0.11 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $12M | — |
| RDIV | 0.81% | $9M | −0.39 pp |
| VONVVanguard Russell 1000 Value ETF | 0.03% | $7M | −0.02 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $7M | — |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.04% | $6M | −0.02 pp |
Showing 10 of 57 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLX Jan avg: 3.63% median: 2.49% win: 75% σ: 5.95% n: 4 2022-04-12 → 2026-07-31 | CLX Feb avg: 6.07% median: 6.49% win: 75% σ: 5.86% n: 4 2022-04-12 → 2026-07-31 | CLX Mar avg: -5.67% median: -2.99% win: 25% σ: 9.15% n: 4 2022-04-12 → 2026-07-31 | CLX Apr avg: -2.39% median: -3.36% win: 20% σ: 4.26% n: 5 2022-04-12 → 2026-07-31 | CLX May avg: -5.64% median: -6.66% win: 20% σ: 4.54% n: 5 2022-04-12 → 2026-07-31 | CLX Jun avg: -0.33% median: 0.54% win: 60% σ: 5.90% n: 5 2022-04-12 → 2026-07-31 | CLX Jul avg: -0.56% median: 0.09% win: 60% σ: 3.65% n: 5 2022-04-12 → 2026-07-31 | CLX Aug avg: 4.79% median: 2.52% win: 75% σ: 10.90% n: 4 2022-04-12 → 2026-07-31 (current) | CLX Sep avg: -5.01% median: -4.07% win: 50% σ: 10.20% n: 4 2022-04-12 → 2026-07-31 | CLX Oct avg: -1.98% median: -5.73% win: 25% σ: 10.98% n: 4 2022-04-12 → 2026-07-31 | CLX Nov avg: 6.25% median: 3.61% win: 75% σ: 11.07% n: 4 2022-04-12 → 2026-07-31 | CLX Dec avg: -3.89% median: -4.22% win: 0% σ: 2.74% n: 4 2022-04-12 → 2026-07-31 |